RxDoctor Payments Data

Bruce Bank, MD

Hematology & Oncology · Elk Grove Village, ILNPI 1225099823

Payments from drug & device makers

$381,938in general payments, 2019–2025

Across 589 payments — averaging $648.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Epizyme, Inc.$89K
  • Partner Therapeutics, Inc.$84K
  • Bristol Myers Squibb$41K
  • G1 Therapeutics, Inc.$30K
  • E.r. Squibb & Sons, L.L.C.$21K
  • Incyte Corporation$21K
  • plus $95K from 54 others
$542in research payments, 2019–2025

Across 1 payment — averaging $541.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$542

What the payments were for

  • Consulting fees$14,45857%
  • Speaking & faculty fees$1,5006%
  • Travel & lodging$490%
  • Food & beverage$9,09036%
  • Education$1731%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Epizyme, Inc.32$89,083
Partner Therapeutics, Inc.3$84,186
Bristol Myers Squibb23$41,179
G1 Therapeutics, Inc.24$30,263
E.r. Squibb & Sons, L.L.C.26$21,320
Incyte Corporation63$21,091
Eli Lilly2$19,520
Pfizer17$18,950
Merck40$13,481
Seagen Inc.15$12,023
AbbVie11$6,476
Acceleron Pharma, Inc.2$4,495
Genentech, Inc.4$4,097
Beigene USA, Inc.9$3,435
Jazz Pharmaceuticals Inc.7$2,895
Johnson & Johnson(2 entities)20$1,782
Taiho Oncology, Inc.2$1,104
Novartis51$961
Genentech USA, Inc.35$607
AstraZeneca(2 entities)26$559
Servier Pharmaceuticals LLC2$454
Amgen15$291
Astellas Pharma US Inc12$277
Sanofi12$253
Regeneron Healthcare Solutions, Inc.8$229
Lilly USA, LLC9$204
Dova Pharmaceuticals3$154
Takeda Pharmaceuticals U.S.A., Inc.7$152
GSK7$143
Gilead(2 entities)7$137
Octapharma USA, Inc.1$126
Agios Pharmaceuticals, Inc.6$120
ADC Therapeutics America, Inc.4$118
Morphosys, US Inc.5$104
Karyopharm Therapeutics Inc.4$100
Daiichi Sankyo Inc.5$98
Deciphera Pharmaceuticals Inc.4$98
Eisai Inc.4$86
CTI Biopharma Corp.4$76
Bayer4$71
EMD Serono, Inc.3$70
Tempus AI, Inc3$69
Stemline Therapeutics Inc.3$67
Puma Biotechnology, Inc.3$65
Verastem, Inc.2$61
Tesaro, Inc.2$56
Pharmacosmos Therapeutics Inc.2$50
Mirati Therapeutics, Inc.2$48
Sobi, Inc2$44
Rigel Pharmaceuticals, Inc.2$39
Clovis Oncology, Inc.2$37
Tersera Therapeutics LLC1$36
AVEO Pharmaceuticals, Inc.2$35
Coherus Oncology, Inc.2$34
Syndax Pharmaceuticals, Inc.1$32
Ipsen Biopharmaceuticals, Inc2$31
Array Biopharma Inc2$30
Beone Medicines USA, Inc.1$27
Exelixis Inc.1$26
Novocure Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381,938 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,988,452
Medicare patients
462
Services billed
102,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide27$605,277
Lenalidomide12$188,241
ImbruvicaIbrutinib12$154,592
XareltoRivaroxaban53$55,628
EliquisApixaban38$25,455
Abiraterone Acetate12$20,829
Hydroxyurea51$1,465
Potassium Chloride36$955
Dexamethasone25$469
Acyclovir40$457
Allopurinol24$437
Gabapentin36$403
Anastrozole17$363
Prochlorperazine Maleate16$231
Warfarin Sodium25$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$41,179$605,27727 claims
Johnson & JohnsonXarelto$1,782$55,62853 claims
PfizerEliquis$18,950$25,45538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →